

Table I. Clinical characteristics of the patients.

N	AGE	TNM	STAGE	SITE*	GRADE	SMOKING**	ALCOHOL***	RECURRENCE OR METASTASIS OR SECOND PRIMARY†
200	58	T4aN0M0	(IVA)	TG	G2	NO	NO	R1, M
201	77	T3N0M0	(III)	G	G2	NO	D	M
202	77	T3N0M0	(III)	G	G2	NO	NO	
203	70	T2N0M0	(II)	G	G2	YES	NO	
204	55	T2N0M0)	(II)	G	G1	YES	NO	R2
206	61	T1aN0M0	(I)	G	G3	YES	NO	
207	57	T2N0M0	(II)	G	G1	YES	D	
208	61	T3N1M0	(III)	SG	G3	YES	H	
209	63	T3N0M0	(III)	G	G2	NO	NO	R1
211	83	T4aN0M0	(IVA)	G	G3	NO	NO	R1, R2
212	62	T3N1M0	(III)	SG	G2	YES	NO	
213	65	T3NxM0	(III)	SG	G2	YES	H	R2
216	71	T3N0M0	(III)	SG	G1	YES	NO	
217	57	T3N0M0	(III)	SG	G2	YES	NO	
218	51	T4aN1M0	(IVA)	G	G2	YES	NO	R1, M
219	74	T3N2cM0	(IVA)	SG	G3	NO	NO	M
220	58	T4aN0M0	(IVA)	SG	G1	YES	NO	
221	56	T3N2cM0	(IVA)	TG	G2	YES	H	
222	59	T4aN0M0	(IVA)	TG	G3	YES	D	
223	76	T3N0M0	(III)	G	G1	YES	D	
224	81	T3N0M0	(III)	G	G2	NO	D	R1
225	54	T3N0M0	(III)	SG	G3	NO	D	
226	63	T3N0M0	(III)	SG	G3	YES	D	
227	78	T3N0M0	(III)	SG	G1	YES	NO	R2
228	61	T2N1M0	(III)	SG	G3	YES	NO	
229	64	T1N0M0	(I)	G	G1	YES	NO	
230	77	T2N1M0	(III)	SG	G3	YES	NO	
231	78	T2N0M0	(II)	G	G2	YES	NO	
232	84	T3N0M0	(III)	TG	G2	YES	NO	R2
233	75	T4aN0M0	(IVA)	TG	G3	YES	D	
234	63	T2N0M0	(II)	G	G1	YES	NO	
235	44	T3N0M0	(III)	G	G2	YES	D	
236	68	T2N3M0	(IVB)	SG	G3	YES	H	M
237	76	T4NxMx	(IV)	TG	G?	YES	NO	R2
238	65	T3N0M0	(III)	SG	G2	YES	NO	R1
239	68	T2N0M0	(II)	G	G2	YES	D	
240	76	T3N0M0	(III)	SG	G1	NO	H	R1
241	73	T2N0M0	(II)	G	G2	NO	NO	
242	61	T3N2cM0	(IVA)	SG	G3	NO	D	P2, M
244	70	T3N0M0	(III)	SG	G1	YES	NO	R1
245	70	T3N0M0	(III)	SG	G2	YES	NO	
246	73	T3N0M0	(III)	SG	G2	YES	NO	R1
247	63	T3N0M0	(III)	SG	G2	YES	D	
248	71	T2N0M0	(II)	G	G1	NO	D	
249	52	T4aN0M0	(IVA)	TG	G2	YES	H	
250	63	T2N0M0	(II)	SG	G2	YES	NO	
251	62	T2N0M0	(II)	G	G2	NO	NO	R1
252	82	T3N0M0	(III)	G	G1	NO	NO	
253	49	T3N0M0	(III)	G	G2	YES	D	

N: code number of individual patient, *G: glottic; SG: supraglottic; TG: transglottic. **NO: refers in all cases to previously smokers.

***NO: drinking alcoholic beverages randomly; D: drinking alcoholic beverages daily; H: drinking heavy quantity of alcoholic beverages daily. †Follow-up information up to 43 months post treatment. R1: Patients included in the study after recurrence of an older primary cancer.

R2: Patients included in the study for a primary cancer, treated and then had a recurrence. M: Patients included in the study for a primary cancer, treated and then metastasized. P2: Second primary.